Does State Medicaid Cover Testosterone Cypionate?

Medicaid Coverage Varies State by State

Coverage for testosterone cypionate under Medicaid is not uniform across the United States. Each state administers its own Medicaid program under federal guidelines, and formulary decisions are made at the state level. The result is a patchwork of policies that can differ in every meaningful way, from copay to clinical criteria.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic androgen deficiency confirmed by reliably low morning serum testosterone concentrations. This recommendation forms the clinical backbone that most state Medicaid programs reference when building their prior authorization criteria. States that carved out pharmacy benefits to managed care organizations (MCOs) add another layer of variability, because each MCO may maintain its own preferred drug list.

As a baseline, generic testosterone cypionate 200 mg/mL intramuscular injection appears on the majority of state Medicaid preferred drug lists. Brand-name Depo-Testosterone carries a list price near $100 per month, while generic versions average $30 to $60 cash pay according to FDA-listed pricing data. States overwhelmingly steer toward the generic. In 2023, CMS reported that Medicaid covered over 83 million Americans, making formulary placement on these programs a significant access question for men with hypogonadism.

Prior Authorization: What Most States Require

Prior authorization is the most common barrier between a prescription and a filled vial. The specific criteria vary, but a recognizable pattern emerges across state Medicaid programs. Expect your prescriber to document the following before the pharmacy can dispense.

First, two separate morning serum total testosterone levels below 300 ng/dL, drawn between 7:00 and 10:00 AM. The Endocrine Society guideline specifies morning draws because testosterone follows a circadian rhythm, peaking in early morning and declining by 30% to 50% through the afternoon. Second, clinical signs or symptoms consistent with androgen deficiency: low libido, erectile dysfunction, fatigue, loss of lean mass, depressed mood, or decreased bone mineral density. Third, exclusion of reversible causes such as opioid use, hyperprolactinemia, or poorly controlled diabetes.

Some states go further. New York's Medicaid program, for example, requires documentation that the patient does not have a contraindication such as untreated polycythemia (hematocrit above 54%), breast cancer, or unevaluated prostate nodules. California's Medi-Cal historically placed testosterone cypionate on its contract drug list without prior authorization for the generic formulation, though MCO carve-outs may still impose their own requirements. Texas Medicaid requires prior authorization and limits initial approvals to 12 months, with re-authorization requiring updated lab work.

The T-Trials, a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, demonstrated that testosterone treatment improved sexual function, physical function, and mood over 12 months. These findings are frequently cited in prior authorization appeals to support the medical necessity of treatment in older men.

Formulary Tier Placement and Cost Sharing

Generic testosterone cypionate sits at Tier 1 or Tier 2 on most state Medicaid preferred drug lists. This matters because tier placement dictates copay. Federal law caps Medicaid copays for preferred generics at nominal amounts, typically $1 to $4 for beneficiaries below 150% of the federal poverty level.

Brand-name Depo-Testosterone, when stocked, usually falls on Tier 3 (non-preferred brand). The copay difference is small in absolute terms for most Medicaid recipients, but it introduces an additional prior authorization step in many states. Prescribers writing for the brand when a generic is available will often trigger an automatic rejection at the pharmacy, requiring either a switch to generic or a medical justification for the brand.

A 10 mL vial of generic testosterone cypionate 200 mg/mL contains enough medication for 10 to 20 weeks of therapy at standard dosing (100 to 200 mg per week or biweekly). At Medicaid pricing, this vial costs the state roughly $15 to $40 through federal rebate agreements. The Medicaid Drug Rebate Program, established under the Omnibus Budget Reconciliation Act of 1990, requires manufacturers to pay rebates to state Medicaid agencies, keeping net costs well below retail.

Step Therapy Requirements

Step therapy, sometimes called "fail first," requires a patient to try and fail a preferred medication before Medicaid will cover an alternative. For testosterone cypionate specifically, step therapy is less common than it is for newer, more expensive formulations like testosterone nasal gel (Natesto) or subcutaneous auto-injectors (Xyosted).

Where step therapy does appear, it typically runs in the opposite direction. Some states require a trial of testosterone cypionate injections before they will authorize topical gels (AndroGel, Testim) or patches (Androderm), because the injectable is far cheaper. Oregon's Medicaid program, for instance, lists testosterone cypionate as the first-line covered formulation and requires failure or documented intolerance before approving topical alternatives.

A smaller number of states flip this sequence. They may require a trial of topical testosterone gel before approving injections, reasoning that gels provide more stable serum levels and reduce the risk of supraphysiologic peaks. The FDA prescribing information for testosterone cypionate notes that intramuscular injections produce peak serum levels within 24 to 48 hours, with a gradual decline over 1 to 2 weeks, creating a pharmacokinetic roller coaster that some clinicians and patients find problematic.

If your state Medicaid program requires step therapy through a topical first, your prescriber can document treatment failure based on inadequate symptom relief, skin reactions, concerns about transference to household contacts (a boxed warning on all topical testosterone products), or patient inability to comply with the application schedule.

How to Appeal a Medicaid Denial

A denial is not the end. Every state Medicaid program is required by federal law to offer a fair-hearing process when a covered service is denied, reduced, or terminated. The CMS Medicaid Fair Hearing requirements under 42 CFR § 431.200 establish minimum procedural protections that all states must follow.

The appeal process generally follows this sequence. Within 10 to 30 days of the denial notice (timeframes vary by state), submit a written appeal through the state Medicaid agency or the MCO that issued the denial. Include a letter of medical necessity from the prescribing physician. Attach lab results showing confirmed low testosterone on two separate morning draws. Reference the Endocrine Society guideline and, where applicable, the T-Trials data showing benefit in symptomatic men. Request an expedited review if the patient is experiencing significant symptoms or if delay poses a health risk.

Dr. Shalender Bhasin, the principal investigator of the T-Trials and professor of medicine at Brigham and Women's Hospital, has stated: "Testosterone treatment of older men with low testosterone improved all aspects of sexual function, increased walking distance, and improved mood" (NEJM, 2016). Including this type of citation from a named investigator and landmark trial strengthens an appeal by demonstrating that testosterone therapy is evidence-based, not experimental.

If the MCO-level appeal fails, you can escalate to a state fair hearing. An administrative law judge reviews the case independently. Success rates at fair hearing vary, but appeals with strong clinical documentation and guideline-concordant prescribing tend to perform well. The entire process, from initial denial to fair hearing decision, typically spans 30 to 90 days.

States with Known Coverage Restrictions

Several states maintain policies that are notably more restrictive or more permissive than the national pattern.

More restrictive states may limit testosterone cypionate coverage to specific ICD-10 codes (E29.1 for testicular hypofunction is the most commonly accepted), require endocrinologist or urologist involvement, or impose age restrictions. Some states exclude coverage for testosterone prescribed to treat age-related decline alone, drawing a line between "classical" hypogonadism (organic causes like Klinefelter syndrome, pituitary tumors, or bilateral orchiectomy) and "functional" or late-onset hypogonadism.

More permissive states cover testosterone cypionate with minimal barriers. California, as noted, has historically placed the generic on its contract drug list without prior authorization. Washington State's Apple Health program covers testosterone cypionate as a preferred drug at the generic level with standard prior authorization.

The American Urological Association's 2018 guideline on testosterone deficiency recommends that clinicians measure total testosterone in patients with signs and symptoms of deficiency and notes that testosterone therapy is indicated when testosterone is unequivocally low. This guideline, alongside the Endocrine Society's, provides the clinical standard that appeals can reference when a state program denies coverage for functional hypogonadism.

Managed Care Organization Carve-Outs

More than 70% of Medicaid beneficiaries are enrolled in managed care plans, according to CMS data. When pharmacy benefits are carved out to an MCO, the MCO's formulary governs, not the state's fee-for-service preferred drug list. This means two Medicaid recipients in the same state, enrolled in different MCOs, may face different coverage rules for the same medication.

Check your specific MCO's formulary rather than relying on the state's published fee-for-service list. MCO formularies are typically available online or by calling the member services number on the back of the Medicaid card. If your MCO denies testosterone cypionate, the appeal first goes through the MCO's internal process before escalating to the state fair hearing.

Testosterone Cypionate for Transgender Hormone Therapy

Medicaid coverage for testosterone cypionate as part of gender-affirming hormone therapy has expanded significantly since the 2016 HHS rule under Section 1557 of the Affordable Care Act prohibited sex-based discrimination in federally funded health programs. As of 2024, at least 26 states and the District of Columbia explicitly cover gender-affirming hormone therapy under Medicaid, though several states have introduced or enacted restrictions.

Prior authorization criteria for gender-affirming testosterone therapy often differ from those for male hypogonadism. States may require documentation of a gender dysphoria diagnosis (ICD-10 F64.0), a letter from a qualified mental health professional, and adherence to WPATH Standards of Care. The Endocrine Society's 2017 guideline on endocrine treatment of gender-dysphoric persons provides the clinical framework referenced by most state Medicaid programs that cover this indication.

Monitoring Requirements That Affect Ongoing Coverage

Medicaid re-authorization for testosterone cypionate typically requires updated lab work. Most states mandate repeat total testosterone levels to confirm the patient is within the therapeutic range (generally 400 to 700 ng/dL at trough), a complete blood count to monitor hematocrit (treatment should be withheld if hematocrit exceeds 54%), and a lipid panel.

The Endocrine Society guideline recommends measuring testosterone and hematocrit at 3 to 6 months after starting therapy, then annually. PSA should be checked at 3 to 12 months in men over 40, per guideline recommendations (though PSA screening itself remains a shared decision per the USPSTF). Failure to provide updated monitoring labs is one of the most common reasons for re-authorization denial. Set reminders for lab draws 4 to 6 weeks before your authorization expiration date.